Appraisals - ASAR & FAR
- 07/08/2019
- Appraisal Report: sitagliptin (Januvia) 1655
-
-
- 27/08/2019
- Appraisal Report: sildenafil (Revatio) 667
-
-
- 09/08/2019
- Appraisal Report: sildenafil (Revatio) 1675
-
-
- 26/06/2019
- Appraisal Report: semaglutide (Ozempic®)
-
-
- 25/07/2019
- Appraisal Report: selexipag (Uptravi) 700
-
-
- 02/08/2019
- Appraisal Report: saxagliptin (Onglyza) 1975
-
-
- 07/08/2019
- Appraisal Report: saxagliptin (Onglyza) 1237
-
-
- 22/08/2019
- Appraisal Report: saxagliptin (Onglyza) 1005
-
-
- 31/07/2019
- Appraisal Report: rituximab (Mabthera) 1048
-
-
- 09/08/2019
- Appraisal Report: rilpivirine (Edurant) 557
-
-
- 09/08/2019
- Appraisal Report: rifaximin (Xifaxanta) 1232
-
-
- 27/08/2019
- Appraisal Report: ranolazine (Ranexa) 723
-
-
- 01/08/2019
- Appraisal Report: prucalopride (Resolor) 918
-
-
- 08/08/2019
- Appraisal Report: perampanel (Fycompa) 1219
-
-
- 02/08/2019
- Appraisal Report: pazopanib (Votrient) 549
-
-